Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients

There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of...

Full description

Saved in:
Bibliographic Details
Published in:Osteoarthritis and cartilage 2019-03, Vol.27 (3), p.484-492
Main Authors: Karsdal, M.A., Verburg, K.M., West, C.R., Bay-Jensen, A.C., Keller, D.S., Arends, R.H.G.P.
Format: Article
Language:English
Subjects:
Biomarker
Clinical study
Osteoarthritis
RPOA2
THR
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of patients. The aim of this study was to phenotype with biochemical biomarkers of bone, cartilage, soft tissue, synovial metabolism OA patients who are at risk of developing RPOA type-2, for both limited and chronic NSAIDs users. The dataset consisted of OA patients participating in tanezumab trials who used NSAIDs
ISSN:1063-4584
1522-9653
DOI:10.1016/j.joca.2018.12.001